ELDN compared with LLY: revenue, margins and what each company keeps, and the suppliers and customers both name

ELDNEledon Pharmaceuticals, Inc.

Mkt capRevenueRevenue

LLYELI Lilly & Co

Mkt capRevenueRevenue

Compare

ELDNEledon Pharmaceuticals, Inc.

LLYELI Lilly & Co

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

ELDNEledon Pharmaceuticals, Inc.

2.44▼−9.45%· post 2.44

Mkt cap$199.9MRevenue—Revenue—

LLYELI Lilly & Co

1,371.32▼−3.29%· post 1,363.77

ClosedNov 5 '26

Mkt cap$1.2TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

Compare

ClosedNov 5 '26

ELDNEledon Pharmaceuticals, Inc.

LLYELI Lilly & Co

2.44▼−9.45%post 2.44

Price

1,371.32▼−3.29%post 1,363.77

$199.9M

Mkt cap

$1.2T

—

Revenue

$24.4BQ3 FY26

—

Revenue

$65.2BFY25

ELDN2.44▼−9.45%vsLLY1,371.32▼−3.29%ClosedNov 5 '26

Earnings history

last 4 reports each · paired by recencyMethod ›

ELDN

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±32.7%▼−4.32%×0.13

May 14 '26±20.1%▲+1.80%×0.09

Q1 FY26±15.7%▲+1.05%×0.07

Q3 FY25±32.9%▼−7.95%×0.24

LLY

3 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±5.1%▲+6.63%×1.29

Q2 FY26±6.2%▲+4.86%×0.79

= impliedELDN realized, solidLLY realized, hatchedOne scale, both sides: full bar = 33%× = |realized| ÷ impliedSource: market data

Q1 FY26

±5.3%

▲+9.80%

×1.85

Feb 4 '26±6.1%▲+10.33%×1.69